Mark Carey
About
Mark Carey is a scholar working on Reproductive Medicine, Molecular Biology and Oncology.
According to data from OpenAlex, Mark Carey has authored 75 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Reproductive Medicine, 33 papers in Molecular Biology and 23 papers in Oncology. Recurrent topics in Mark Carey's work include Ovarian cancer diagnosis and treatment (33 papers), Cancer Genomics and Diagnostics (11 papers) and Endometrial and Cervical Cancer Treatments (11 papers). Mark Carey is often cited by papers focused on Ovarian cancer diagnosis and treatment (33 papers), Cancer Genomics and Diagnostics (11 papers) and Endometrial and Cervical Cancer Treatments (11 papers). Mark Carey collaborates with scholars based in Canada, United States and Ireland. Mark Carey's co-authors include Gordon B. Mills, Bryan T. Hennessy, Gökhan S. Hotamışlıgil, Kristin M. Nieman, Rebecca Buell‐Gutbrod, Marcus E. Peter, Katja Gwin, S. Diane Yamada, András Ladányi and Marion Zillhardt and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.
In The Last Decade
Mark Carey
73 papers receiving 5.0k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Mark Carey Canada | 32 | 2.5k | 1.8k | 1.6k | 1.3k | 558 | 75 | 5.1k | ||
| Nicoletta Biglia Italy | 41 | 1.4k 0.6× | 1.6k 0.9× | 1.3k 0.8× | 703 0.5× | 416 0.7× | 195 | 5.0k | ||
| Helga B. Salvesen Norway | 49 | 3.0k 1.2× | 1.6k 0.9× | 1.5k 0.9× | 1.8k 1.3× | 2.6k 4.6× | 153 | 6.9k | ||
| Jun‐ichi Akahira Japan | 37 | 1.4k 0.6× | 841 0.5× | 756 0.5× | 730 0.5× | 667 1.2× | 108 | 3.6k | ||
| Nicole Concin Austria | 37 | 1.3k 0.5× | 1.4k 0.8× | 777 0.5× | 1.2k 0.9× | 1.0k 1.8× | 146 | 3.9k | ||
| Rouba Ali‐Fehmi United States | 39 | 1.2k 0.5× | 811 0.5× | 874 0.5× | 1.3k 1.0× | 1.6k 2.8× | 152 | 4.2k | ||
| Barbara Schmalfeldt Germany | 33 | 1.2k 0.5× | 1.5k 0.9× | 855 0.5× | 1.1k 0.8× | 433 0.8× | 130 | 4.2k | ||
| P Sismondi Italy | 47 | 1.7k 0.7× | 2.7k 1.5× | 1.8k 1.1× | 987 0.7× | 868 1.6× | 188 | 6.9k | ||
| Gilad Ben‐Baruch Israel | 39 | 1.4k 0.6× | 995 0.6× | 657 0.4× | 1.7k 1.3× | 1.3k 2.3× | 152 | 4.7k | ||
| Hatem A. Azim Belgium | 36 | 1.3k 0.5× | 3.6k 2.0× | 1.6k 1.0× | 703 0.5× | 144 0.3× | 120 | 5.5k | ||
| Norio Wake Japan | 40 | 1.8k 0.7× | 684 0.4× | 688 0.4× | 425 0.3× | 820 1.5× | 171 | 4.6k |
Countries citing papers authored by Mark Carey
Since
Specialization
Citations
This map shows the geographic impact of Mark Carey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Carey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Carey more than expected).
Fields of papers citing papers by Mark Carey
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Mark Carey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Carey. The network helps show where Mark Carey may publish in the future.
Co-authorship network of co-authors of Mark Carey
This figure shows the co-authorship network connecting the top 25 collaborators of Mark Carey. A scholar is included among the top collaborators of Mark Carey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Carey. Mark Carey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fernández, Marta Llauradó, Linda S. Cook, Stéphanie Gaillard, et al.. (2025). FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma. Journal of Gynecologic Oncology. 36(5). e74–e74.
2.
Hollis, Robert L., Richard Elliott, John C. Dawson, et al.. (2024). High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecologic Oncology. 186. 42–52.
3.
Wong, Nelson K.Y., Marta Llauradó Fernández, Hannah Kim, et al.. (2024). Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer. Gynecologic Oncology. 188. 162–168.
4.
Tessier‐Cloutier, Basile, Keiyan Sy, Guangming Han, et al.. (2024). Ovarian carcinosarcomas: p53 status defines two distinct patterns of oncogenesis and outcomes. Frontiers in Oncology. 14. 1408196–1408196.
5.
Nasioudis, Dimitrios, Nawar Latif, Emily Ko, et al.. (2023). Impact of adjuvant chemotherapy on the overall survival of patients with advanced-stage low-grade serous ovarian carcinoma following primary cytoreductive surgery. International Journal of Gynecological Cancer. 33(12). 1906–1912.
6.
Nasioudis, Dimitrios, Marta Llauradó Fernández, Nelson K.Y. Wong, et al.. (2023). The spectrum of MAPK-ERK pathway genomic alterations in gynecologic malignancies: Opportunities for novel therapeutic approaches. Gynecologic Oncology. 177. 86–94.
7.
Straneo, Fiammetta, Donald Slater, Caroline Bouchard, et al.. (2022). An Interdisciplinary Perspective on Greenland’s Changing Coastal Margins. Oceanography.
8.
Fernández, Marta Llauradó, E. Marielle Hijmans, Annemiek M.C. Gennissen, et al.. (2022). NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition. Molecular Cancer Therapeutics. 21(12). 1862–1874.
9.
Shrestha, Raunak, Marta Llauradó Fernández, Amy Dawson, et al.. (2021). Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability. Cancer Research. 81(7). 1681–1694.
10.
Dawson, Amy, Marta Llauradó Fernández, Michael S. Anglesio, Paul J. Yong, & Mark Carey. (2018). Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development. ecancermedicalscience. 12. 803–803.
11.
Huggel, Christian, Imtiaz Rangwala, Nadine Salzmann, et al.. (2015). The High-Mountain Cryosphere. Cambridge University Press eBooks.
12.
Stordal, Britta, Kirsten M. Timms, Angela M. Farrelly, et al.. (2013). BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Molecular Oncology. 7(3). 567–579.
13.
Carey, Mark, Roshan Agarwal, C. Blake Gilks, et al.. (2010). Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy. Clinical Cancer Research. 16(10). 2852–2860.
14.
Park, Eun Sung, Rosalia Rabinovsky, Mark Carey, et al.. (2010). Integrative Analysis of Proteomic Signatures, Mutations, and Drug Responsiveness in the NCI 60 Cancer Cell Line Set. Molecular Cancer Therapeutics. 9(2). 257–267.
15.
Perren, Timothy, Jacobus Pfisterer, JA Ledermann, et al.. (2010). ICON7: A PHASE III RANDOMISED GYNAECOLOGIC CANCER INTERGROUP TRIAL OF CONCURRENT BEVACIZUMAB AND CHEMOTHERAPY FOLLOWED BY MAINTENANCE BEVACIZUMAB, VERSUS CHEMOTHERAPY ALONE IN WOMEN WITH NEWLY DIAGNOSED EPITHELIAL OVARIAN (EOC), PRIMARY PERITONEAL (PPC) OR FALLOPIAN TUBE CANCER (FTC). UCL Discovery (University College London).
16.
Agarwal, Roshan, Simen Myhre, Mark Carey, et al.. (2009). Integrative Analysis of Cyclin Protein Levels Identifies Cyclin B1 as a Classifier and Predictor of Outcomes in Breast Cancer. Clinical Cancer Research. 15(11). 3654–3662.
17.
Hennessy, Bryan T., Yiling Lu, Enrique Poradosu, et al.. (2007). Pharmacodynamic Markers of Perifosine Efficacy. Clinical Cancer Research. 13(24). 7421–7431.
18.
Kwon, Janice S., John Lenehan, Mark Carey, & Peter Ainsworth. (2007). Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series. International Journal of Gynecological Cancer. 18(3). 546–549.
19.
Yeh, Fa-Lai, et al.. (1990). Comparison of Scar Contracture with the Use of Microskin and Chinese-Type Intermingled Skin Grafts on Rats. Journal of Burn Care & Rehabilitation. 11(3). 221–223.
20.
Gardner, R. L., et al.. (1988). Effect of delayed implantation on differentiation of the extra-embryonic endoderm in the mouse blastocyst. Placenta. 9(4). 343–359.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nicoletta Biglia Breakdown of academic impact, for papers by Helga B. Salvesen Breakdown of academic impact, for papers by Jun‐ichi Akahira Breakdown of academic impact, for papers by Nicole Concin Breakdown of academic impact, for papers by Rouba Ali‐Fehmi Breakdown of academic impact, for papers by Barbara Schmalfeldt Breakdown of academic impact, for papers by P Sismondi Breakdown of academic impact, for papers by Gilad Ben‐Baruch Breakdown of academic impact, for papers by Hatem A. Azim Breakdown of academic impact, for papers by Norio Wake